Dr. Kumar’s lab develops immunotherapies targeting viral antigens. They have developed in-house naive universal phage display scFv and nanobody libraries that can be potentially used to isolate antibodies against diverse target antigens. Additionally, the library’s ability to select binders with nanomolar affinity from a variety of targets offers substantial advantages for applications in drug discovery, diagnostic assays, and therapeutic development. His work on developing biotechnology innovation platforms focuses on accelerating antibody discovery using high-diversity nanobody libraries, phage display screening, and advanced antibody engineering technologies. Kumar is also the Director of AbSure Biosciences Pvt. Ltd., which focuses on developing Next-Generation Biologics for Therapeutics, Diagnostics & Research.